|
Synonyms: Entyvio® | LDP-02 | LDP02 | MLN-0002 | MLN-002 | MLN002
vedolizumab is an approved drug (FDA and EMA (2014))
Compound class:
Antibody
Comment: The peptide sequences for the heavy and light chains that form this antibody are annotated in its IMGT/mAb-DB record.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖
View more information in the IUPHAR Pharmacology Education Project: vedolizumab |
| No information available. |
Summary of Clinical Use  |
| Approved to treat adult patients with moderate to severe ulcerative colitis or moderate to severe Crohnâs disease. |
| Mechanism Of Action and Pharmacodynamic Effects |
| This antibody binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1) [2]. α4β7 integrin directs leukocytes to mucosal and inflamed tissues. This integrin is only expressed on subsets of leukocytes, and this is found to restrict α4β7-induced inflammatory modulation to the gut [2]. Specifically, vedolizumab inhibits binding of α4β7 expressing leukocytes to mucosal addressin cell adhesion molecule 1 (MADCAM1, a lymphocyte homing receptor) and fibronectin, but not to vascular cell adhesion protein 1 (VCAM1) [2]. This has the effect of reducing bowel inflammation in patients with indicated conditions. |
| External links |
|
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |
